CMC stands for Chemistry, Manufacturing, and Controls. It’s the body of information that proves a drug or biologic is what it claims to be, is made consistently, and is safe to give to people. Every company developing a therapeutic product must compile CMC data before running clinical trials and again before seeking market approval. In biotech, where products are complex proteins, antibodies, or cell therapies, CMC work is one of the most resource-intensive parts of bringing a treatment to market.
The Three Pillars of CMC
Each word in the acronym covers a distinct set of requirements. “Chemistry” refers to the composition and characterization of both the drug substance (the active ingredient) and the drug product (the final formulation a patient receives). This includes understanding the molecular structure, identifying impurities, and defining the quantitative composition of every component.
“Manufacturing” covers the entire production process, from raw materials and starting biological materials through each step that yields the final product. Companies must document their manufacturing procedures, qualify critical equipment, and validate that the process reliably produces the same result batch after batch. Standard operating procedures must be written for every stage of production and testing.
“Controls” is the quality system that ties everything together. It includes the analytical tests used to confirm a product’s identity, strength, purity, and stability, along with the acceptance criteria each batch must meet before it can be released. Specifications must list every known impurity, whether organic, inorganic, or residual solvents, with limits set based on both safety data and what the manufacturing process can realistically achieve.
Why CMC Matters for Patient Safety
The FDA requires that “sufficient information should be submitted to assure the proper identification, quality, purity, and strength of the investigational drug” at every phase of development. CMC data is the mechanism for that assurance. If a company changes its manufacturing process between animal studies and human trials, any differences in the resulting product must be described, along with an explanation of how safety risks will be addressed.
This isn’t just paperwork. Biologics are produced by living cells, meaning tiny shifts in temperature, timing, or raw materials can alter the final product in ways that affect how it works in the body. CMC controls are what prevent a batch used in a Phase 3 trial from being subtly different from the batch that showed promise in Phase 1. Without that consistency, clinical trial results become unreliable, and patients face unpredictable risks.
CMC Across the Drug Development Timeline
CMC work begins early and never really stops. During discovery and preclinical development, scientists establish basic characterization of the drug substance and develop preliminary manufacturing processes. Before filing an Investigational New Drug (IND) application to start human trials, companies must submit CMC data covering the drug substance, drug product, packaging, stability, and labeling. At this stage, the FDA places particular emphasis on understanding the new drug substance and its raw materials.
The level of detail expected increases with each clinical phase. In Phase 1, preliminary stability data from representative batches is sufficient. By the time a company files for full approval (through a New Drug Application or Biologics License Application), the CMC section must be comprehensive. The FDA’s quality assessment at that point evaluates the drug substance, drug product, manufacturing process, facilities, and microbiology surveillance, often alongside a facility inspection.
All of this CMC information lives in Module 3 of the Common Technical Document, an internationally harmonized format used for regulatory submissions across the U.S., Europe, and Japan. Module 3 is dedicated entirely to quality data and is structured around two main sections: drug substance and drug product. It also includes a pharmaceutical development section that explains the scientific rationale behind formulation and process decisions.
What Makes Biologics CMC More Complex
Small molecule drugs, like a typical pill, have simple, well-defined chemical structures. You can fully characterize them with standard analytical techniques, and two manufacturers following the same chemical synthesis will produce identical molecules. Biologics are fundamentally different. They’re large, structurally complex molecules produced by living systems, and the manufacturing process itself becomes a defining characteristic of the product. The phrase “the process is the product” is a common refrain in biologics development for exactly this reason.
This complexity shows up in several ways. Biologics are sensitive to storage conditions and can degrade through pathways that small molecules don’t experience, like aggregation or changes in protein folding. Characterization requires more sophisticated testing. Impurity profiles are harder to define because the biological production system introduces a wider range of potential contaminants, from host cell proteins to residual DNA. And because biologics can trigger immune responses in patients, CMC data must address antigenicity in ways that small molecule programs typically don’t.
These challenges are also why biosimilars (the biologic equivalent of generic drugs) face a much higher regulatory bar than traditional generics. A generic small molecule just needs to show it has the same chemical structure. A biosimilar must demonstrate through extensive analytical, functional, and clinical comparisons that it is highly similar to the original, with no meaningful differences in safety or effectiveness.
Stability Testing Requirements
Stability data is a core component of every CMC submission. The goal is to prove that the drug substance and drug product remain safe and effective throughout their intended shelf life, under the storage conditions listed on the label. For IND submissions, companies submit preliminary stability data from representative batches, such as technical or nonclinical batches, along with whatever data is available from clinical batches.
Drug product stability testing goes further than just monitoring potency over time. It must also cover in-use compatibility (how the product holds up once prepared for administration), reconstitution stability for products that are mixed before use, and data supporting any hold times during manufacturing. Forced degradation studies, which deliberately expose the product to stress like heat, light, and humidity, help identify the pathways by which a product breaks down, informing both the shelf life and the analytical methods used to detect degradation.
Post-Approval CMC Changes
Getting a drug approved doesn’t end CMC obligations. Any change to the approved manufacturing process, even a seemingly minor one, must be reported to the FDA. Changes fall into three categories based on their potential impact on product quality.
- Major changes require a prior approval supplement. The company must submit data and receive FDA approval before distributing any product made with the new process.
- Moderate changes require a supplement filed at least 30 days before distribution, or in some cases at the time of distribution.
- Minor changes can be implemented immediately but must be documented in the company’s annual report to the FDA, including a summary of studies performed to assess the change’s effect on quality.
For every category, companies must assess the impact on product quality through appropriate studies and keep executed batch records, standard operating procedures, and test data on file for FDA inspection. Ongoing requirements also include validating test methods, qualifying equipment, and maintaining the manufacturing process in a state of control, which may involve additional process validation and stability studies depending on the nature of the change.
CMC’s Role in Biotech Organizations
In practice, CMC is both a regulatory discipline and a functional team within biotech companies. CMC groups typically include analytical chemists, process development scientists, quality assurance specialists, and regulatory affairs professionals. For small biotech startups, CMC can represent one of the biggest bottlenecks in getting to clinical trials, because the work is technically demanding, time-consuming, and non-negotiable from a regulatory standpoint.
Many companies outsource portions of CMC work to contract development and manufacturing organizations, particularly for early-stage programs. But responsibility for the CMC data in a regulatory submission always rests with the sponsor company. A CMC deficiency is one of the most common reasons the FDA issues a clinical hold on an IND application or requests additional information before approving a product, making it one of the areas where biotech companies can least afford to cut corners.